Applied Sciences · 2020 · 13 citations · 95 references
Veterinary MedicineImmunologyInfectious DiseasesAntimicrobial ResistanceHost-pathogen InteractionsInflammationAntibacterial TherapyAntibiotic ResistancePulmonary TuberculosisTargeted Antimicrobial TherapyTuberculosis CareTuberculosis PharmacotherapyHost Immune Response ModulationHost-directed TherapyMultidrug-resistant Tuberculosis TreatmentMycobacterium Tuberculosis InfectionMycobacterium Tuberculosis PathogenesisPhagocyte Antimicrobial ActivityTuberculosis Drug DevelopmentTuberculosis Drug Resistance
Despite global efforts to contain tuberculosis (TB), the disease remains a leading cause of morbidity and mortality worldwide, further exacerbated by the increased resistance to antibiotics displayed by the tubercle bacillus Mycobacterium tuberculosis. In order to treat drug-resistant TB, alternative or complementary approaches to standard anti-TB regimens are being explored. An area of active research is represented by host-directed therapies which aim to modulate the host immune response by mitigating inflammation and by promoting the antimicrobial activity of immune cells. Additionally, compounds that reduce the virulence of M. tuberculosis, for instance by targeting the major virulence factor ESX-1, are being given increased attention by the TB research community. This review article summarizes the current state of the art in the development of these emerging therapies against TB.
95
Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response
Philip T. Liu, Steffen Stenger, Huiying Li et al. · Science · 2006 · 3.9K citations